#1 Clinical Trials Search in Europe

Dabrafenib

Dabrafenib, also known as GSK2118436, is a promising drug being studied in clinical trials for various types of cancer, particularly those with BRAF mutations. This article explores the use of Dabrafenib in clinical trials, its potential benefits, and its impact on patients’ quality of life. We’ll look at its applications in melanoma, thyroid cancer, and other solid tumors, as well as its safety profile and effectiveness when used alone or in combination with other drugs.

Table of Contents

What is Dabrafenib?

Dabrafenib is a medication used in the treatment of certain types of cancer. It is also known by its brand name Tafinlar and is sometimes referred to by its research code GSK2118436[6]. Dabrafenib belongs to a class of drugs called BRAF inhibitors, which target a specific genetic mutation found in some cancer cells[2].

How Dabrafenib Works

Dabrafenib works by blocking a protein called BRAF, which plays a central role in the growth and survival of cancer cells with a specific genetic mutation called BRAF V600. By inhibiting this protein, Dabrafenib can help slow down or stop the growth of cancer cells[3].

The BRAF mutation is like a faulty switch that keeps cancer cells growing uncontrollably. Dabrafenib acts like a targeted “off switch” for this faulty mechanism, potentially slowing or stopping cancer growth.

Conditions Treated with Dabrafenib

Dabrafenib is primarily used to treat the following conditions:

  • Melanoma: A type of skin cancer, particularly when it has spread to other parts of the body (metastatic) or cannot be removed by surgery[4].
  • Non-small cell lung cancer: A type of lung cancer with the BRAF V600E mutation[1].
  • Anaplastic thyroid cancer: An aggressive form of thyroid cancer[1].
  • Other solid tumors: Dabrafenib is being studied for use in other types of cancers that have the BRAF V600 mutation[1].

Combination Therapy with Trametinib

Dabrafenib is often used in combination with another drug called Trametinib (brand name Mekinist). This combination therapy has shown improved effectiveness in treating certain cancers compared to using Dabrafenib alone[4].

The combination works by targeting two different parts of the same cellular pathway. While Dabrafenib blocks the BRAF protein, Trametinib inhibits another protein called MEK. This dual approach can lead to better cancer control and may help prevent or delay the development of drug resistance.

How Dabrafenib is Administered

Dabrafenib is typically taken orally in capsule form. The usual dose is 150 mg twice daily, approximately 12 hours apart[5]. However, the exact dosage and schedule may vary depending on the specific condition being treated and the patient’s individual factors. It’s crucial to take Dabrafenib exactly as prescribed by your healthcare provider.

Clinical Trials and Research

Numerous clinical trials have been conducted to study the effectiveness and safety of Dabrafenib. These trials have investigated its use in various stages of melanoma, including:

  • As an adjuvant treatment (after surgery) for high-risk melanoma to prevent recurrence[5].
  • In combination with Trametinib for advanced melanoma that has spread to the brain[2].
  • For other types of cancers with the BRAF V600 mutation, such as thyroid cancer[3].

Ongoing research continues to explore new potential uses for Dabrafenib and ways to optimize its effectiveness.

Potential Side Effects

Like all medications, Dabrafenib can cause side effects. Some of the most common side effects include:

  • Fever (pyrexia)
  • Fatigue
  • Skin changes (rash, dry skin)
  • Headache
  • Joint pain

More serious side effects can occur, although they are less common. These may include the development of new skin cancers, eye problems, or heart rhythm changes[6]. It’s important to report any new or worsening symptoms to your healthcare provider promptly.

Patient Monitoring During Treatment

While on Dabrafenib treatment, patients typically undergo regular monitoring. This may include:

  • Blood tests to check liver function and other health markers[6].
  • Heart monitoring with electrocardiograms (ECGs)[2].
  • Skin examinations to check for new skin cancers[6].
  • Eye exams to check for any vision changes[6].
  • Imaging scans to assess the cancer’s response to treatment[5].

These monitoring procedures help ensure the treatment is working effectively and allow for early detection of any potential side effects.

Aspect Details
Drug Name Dabrafenib (GSK2118436)
Primary Uses Treatment of BRAF V600 mutation-positive cancers, including melanoma and solid tumors
Administration Oral capsules, typically 150 mg twice daily
Combination Therapy Often used with Trametinib (Mekinist)
Key Clinical Trials NCT01266967, NCT01682213, NCT01534897, NCT04547946
Primary Outcomes Overall Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS)
Secondary Outcomes Quality of Life, Duration of Response, Safety Profile
Notable Side Effects Fever (pyrexia), fatigue, skin changes, headache
Special Populations Studied in patients with brain metastases and pediatric patients

FAQ

  • What is Dabrafenib and how does it work? Dabrafenib (GSK2118436) is an orally administered BRAF inhibitor. It works by targeting and blocking the activity of mutated BRAF proteins, which are involved in the growth and survival of certain cancer cells, particularly in melanoma and other solid tumors with BRAF V600 mutations.
  • What types of cancer is Dabrafenib being studied for? Dabrafenib is being studied in clinical trials for various types of cancer, including melanoma (especially those with brain metastases), papillary thyroid carcinoma, and other BRAF mutation-positive solid tumors.
  • Is Dabrafenib used alone or in combination with other drugs? Dabrafenib is being studied both as a single agent and in combination with other drugs. For example, it's often used in combination with Trametinib (Mekinist) for the treatment of melanoma.
  • What are some common side effects of Dabrafenib? Common side effects of Dabrafenib may include fever (pyrexia), fatigue, skin changes, and headache. However, the full safety profile is still being studied in clinical trials.
  • How is the effectiveness of Dabrafenib measured in clinical trials? The effectiveness of Dabrafenib is measured through various outcomes, including overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and quality of life assessments. Researchers also look at tumor shrinkage and the duration of response to the treatment.

Ongoing Clinical Trials on Dabrafenib

  • Study on Dabrafenib, Trametinib, and Imatinib for Patients with Rare and Hard-to-Treat Cancers

    Recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Study on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Study on the Effectiveness of Pembrolizumab and Ipilimumab in Melanoma Patients with Brain Metastases Requiring Steroid Treatment

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark

  • Study of Drug Combination Treatment Based on Tumor Molecular Changes in Patients with Advanced or Metastatic Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Drug Combination for Advanced Cancer Patients with Known Molecular Profile – FINPROVE Study

    Recruiting

    1 1 1
    Investigated drugs:
    Finland

  • Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • A Study of Dabrafenib and Trametinib Treatment Before and After Surgery in Patients with Papillary Craniopharyngioma

    Recruiting

    1 1 1
    Investigated drugs:
    Sweden

  • Molecularly Tailored Therapy Versus Standard Care in Patients With Advanced Pancreatic Cancer Using Olaparib, Erlotinib, Crizotinib, Trametinib, Pemigatinib, Selpercatinib, Axitinib, Vismodegib, Pembrolizumab, Larotrectinib, Dabrafenib, Capecitabine, Oxaliplatin, Fluorouracil, Irinotecan, Gemcitabine, Paclitaxel Albumin-Bound, and Calcium Folinate

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Denmark

  • Study of dabrafenib and trametinib combination therapy before and after surgery in patients with BRAF-mutated anaplastic thyroid cancer

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Advanced Soft-Tissue Sarcoma: Testing Futibatinib and Drug Combination for Patients with Unresectable or Metastatic Conditions

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • BRAF: A gene that makes a protein called B-Raf, which is involved in sending signals in cells and in cell growth. This gene may be mutated (changed) in many types of cancer, including melanoma and colorectal cancer.
  • V600 mutation: A specific mutation in the BRAF gene that is found in many melanomas and some other cancers. This mutation causes the BRAF protein to be constantly active, leading to uncontrolled cell growth.
  • Metastatic: Cancer that has spread from the primary site of origin to other parts of the body.
  • Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment for a disease that patients are still alive.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.

References

  1. https://clinicaltrials.gov/study/NCT06262919
  2. https://clinicaltrials.gov/study/NCT01266967
  3. https://clinicaltrials.gov/study/NCT01534897
  4. https://clinicaltrials.gov/study/NCT04547946
  5. https://clinicaltrials.gov/study/NCT01682213
  6. https://clinicaltrials.gov/study/NCT00880321